chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pain @ inject site immed p/vax; pain worse & radiated back of arm & to breast area; by that evening an orange sized swollen area has devel in upper arm, hot to touch; applied cold packs; that noc noticed an ecchymosis & 8 hive like lesions;
There was a vaccine error with Kinrix Dtap/IPV. Upon checking patient's Immunization list and doing the prediction check. Dtap and IPV were one of the vaccines needed. I scanned the Kinrix and along with the Hep A Vaccine. An alert came up,  I then took the vaccines to Dr. to verify and approve. The vaccine was administered to the patient.
pt recvd vax & w/in 48 hrs pt devel soreness @ inject site;
I tested positive for COVID-19 on 12/03/22. I had a sore throat, and a fever. I woke up in the night to urinate several times and that is not normal for me. I went to the kitchen to get a glass of water and fainted. When I fell, I fell on the glass and was bleeding heavily. I had to go to the emergency room, and I was released later that day. I was not prescribed medication. I am feeling better now.
This case was reported by a pharmacist via call center representative and described the occurrence of fatigue in a 54-year-old female patient who received SHINGRIX (batch number L9CS4, expiry date 20th April 2021) for prophylaxis. On 21st July 2018 13:00, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 21st July 2018, several hours after receiving SHINGRIX, the patient experienced injection site erythema and injection site swelling. On 21st July 2018 21:00, the patient experienced fatigue, attention concentration difficulty and activities of daily living impaired. On an unknown date, the outcome of the fatigue, injection site erythema, injection site swelling and attention concentration difficulty were not recovered/not resolved and the outcome of the activities of daily living impaired was unknown. The reporter considered the fatigue, injection site erythema, injection site swelling, attention concentration difficulty and activities of daily living impaired to be probably related to SHINGRIX. Additional details were provided as follows: The patient was small and petite in her body type. On 21st July 2018 (Saturday), the patient received SHINGRIX on left deltoid. In evening at 21:00 pm, 8 hours after receiving SHINGRIX, the patient started feeling fatigue and lack of focus and went to bed and slept until 23rd July 2018 (Monday). The patient also had redness and swelling at the injection site. At the time of this report, the patient was fatigued; she could not able to focus. The patient was sent home from work on the reporting date. The patient did not receive any treatment for these adverse events and she had rested at home only.
Pt recvd 2nd dose of Hep B 8DEC89 & 2 days later the rash recurred; rash cont to occur on periodic basis; on 29MAY90 pt exp SOB; 28DEC90 presented to ER w/reoccurrence of rash;
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 09-FEB-2009, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided), as recommended for routine adult health maintenance and for the long-term prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster or shingles. On or about 20-MAR-2016, the patient was treated for the onset of a vesicular rash, which was diagnosed as severe herpes zoster or shingles. On or about 21-MAR-2016, the patient sought subsequent treatment from an optometrist for the onset of another vesicular rash, which was diagnosed as severe herpes zoster or shingles. The outcome of the events is unknown. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering and other damages. Additional information has been requested.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Flushed / Sweating-Mild, Additional Details: pt treated palliatively and supported until felt well. attempted to call ems but upon triaging via phone pt rebounded. pt was sweating and lightheaded. provided cool damp towelette to cool down and gave minutemaid orange juice, water and peanut butter crackers. pt left after about 45 minutes with spouse.
I had a rash/hive break out all over body. It started the day after second vaccination shot and continues today(5 days later) I have consulted with doctor as to what his recommendations were. I am taking antihistamines orally and applying a Benadryl cream topically. I get relief from symptoms for about 8-10 hours then it reoccurs. I have photographs if I am able to upload them to you as needed.
2nd day Swollen lymph nodes under right arm, which was arm received shot in.; Nausea all day 2nd and 3rd day after shot; Muscle aches; Joint pain; 3rd shot Booster-bad headache & fatigue day of shot; 3rd shot Booster-bad headache & fatigue day of shot; This is a spontaneous report from a contactable reporter (consumer or other non-HCP). The reporter is the patient.  A 57-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in right arm, administration date 26Feb2022 at 13:00 (Lot number: FK9895) at the age of 57 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Breast cancer" (unspecified if ongoing); "Blood pressure high" (unspecified if ongoing), notes: High BP; "Obesity" (unspecified if ongoing), notes: Obese; "Reaction to sulfites" (unspecified if ongoing), notes: Known allergies: Sulfites and "Latex allergy" (unspecified if ongoing), notes: Known allergies: Latex. Concomitant medications included: CITALOPRAM; ROSUVASTATIN; EXEMESTANE and LOSARTAN POTASSIUM. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot number: ER8727; Anatomical location: Right arm), administration date: 25Mar2021, when the patient was 56 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE; Lot number: ER8731; Anatomical location: Right arm), administration date: 15Apr2021, when the patient was 56 years old, for COVID-19 immunisation.  The following information was reported: HEADACHE (non-serious) with onset 26Feb2022, outcome "recovered" (an unknown date in 2022), described as "3rd shot Booster-bad headache & fatigue day of shot"; FATIGUE (non-serious) with onset 26Feb2022, outcome "recovered" (an unknown date in 2022), described as "3rd shot Booster-bad headache & fatigue day of shot"; LYMPHADENOPATHY (non-serious) with onset 27Feb2022 at 13:00, outcome "recovered" (an unknown date in 2022), described as " 2nd day Swollen lymph nodes under right arm, which was arm received shot in"; NAUSEA (non-serious) with onset 27Feb2022 at 13:00, outcome "recovered" (an unknown date in 2022), described as "Nausea all day 2nd and 3rd day after shot"; MYALGIA (non-serious) with onset 27Feb2022 at 13:00, outcome "recovered" (an unknown date in 2022), described as "Muscle aches"; ARTHRALGIA (non-serious) with onset 27Feb2022 at 13:00, outcome "recovered" (an unknown date in 2022), described as "Joint pain". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of headache, fatigue, lymphadenopathy, nausea, myalgia and arthralgia.  Additional information: Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient reported that she had breast cancer 7 years ago on left side. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19 and the result was negative.  No follow-up attempts are possible. No further information is expected.
Mom describes fever of 102 on 16JAN92; cold sx, cough times 3-4 days; Seen by MD 17JAN92 "viral infect" prescribed Dimetapp & APAP;
Systemic: Dizziness/Lightheadedness-Severe, Systemic: Fainting/Unresponsive-Severe, Systemic: Nausea-Severe, Additional Details: Patient fainted within 2 minutes of receiving COVID-19 booster vaccine and Influenza vaccine, for approximately 10 seconds. She regained consciousness and still felt very nauseous/dizzy/weak for the remainder of observation for about 1 hour. At the patient's request, we called EMS. They picked her up and took her away on a stretcher. We haven't heard from the patient since.
I was 4 weeks pregnant at the time I received the second dose of my Covid vaccine. This was unknown to me at the time. I had a miscarriage around 2 weeks later.
held upright d/u diff breathing;mom states that pt sounded congested but no nasal drainage;cough & gasp for breath;17SEP98 lungs not congested;T99.6;temp @ home on 16SEP98 T100.4;17SEP98 8PM T101;
6/22/18 Visit: Patient has what looks like some type of allergic reaction, possible it is to the vaccines but could also be to something else. Almost look like bug bites but I think it is more of an urticaria. Around the umbilicus I think he has scratched so much it is more irritated. With the redness and swelling of the left knee I want to get some labs today. No fever and looks well when he is in the hallway but concerned about him walking oddly. Will have him do BENADRYL every 6-8 hours and return in the morning for repeat evaluation. If overnight he has increased fussiness, new fever, looking more ill Mom to call or take him into the ED for further evaluation. Call with any questions or concerns. Should have the results on the labs back by tomorrow. Dr. came to evaluate the patient also and agreed with this plan. 6/23/2018 Visit: 2yo here with rash. Rash is most consistent with serum-sickness like reaction, given its appearance and the lack of fever and mucus membrane involvement. It could be related to recent vaccines (PREVNAR and Hep A); there are case reports of serum sickness like reaction after pneumococcal vaccine. Patient is now UTD on both Hep A and PREVNAR vaccines so he will not need them again. Rash scattered everywhere--red raised blanching patches, coalescing in bilat axillae, on lower belly and in diaper zone sparing penis and scrotum. A few spots on buttocks. Patch on lateral abdomen with raised and circular lesions. Purple discoloration in center of lesions around umbilicus and on post left knee.
Headache, soreness in arm after shots and very tired. 6 weeks after 3rd booster shot, My mother did not recall visiting me and my family for late November holiday with her husband. She also did not recall that her 9 year old grandaughter had surgery December 6 . Memory issues kept occurring and my mother continued to be extremely confused during our conversations getting information, dates, names etc. mixed up. She also kept falling at her home and hitting her head. August 22, 2022 everything changed. She was rushed to the ER and we were told she had a meningioma in her left frontal lobe and dementia. No one on her side of the family has had either brain tumor or dementia.
pt recv vax 8MAR95, lt hospital that same day started having fever of 100.3 went up to 101.4; was taken to ER & adm for tests; all tests were neg; MD did not think illness was assoc w/vax;
Vaccine Meningococcal MCV4 Menquadfi was administered to patient before mentioned. For no  known reason, the vaccine was showing in health maintenance when administered it showed as an error in ALERT. Provider on site was notified as well as the patient. Patient was in observation for over 40 minutes and no reactions were presented.
Info has been received from a registered nurse concerning a 73 year old female with allergies to penicillin and sulfa and was noted to be "healthy" at the time of vaccination who on 10/23/2002 was vaccinated with a 2nd dose of pneumococcal vaccine 23 polyvalent (lot 642749/0111M) IM in the right deltoid. On 10/22/2002, the pt was concomitantly vaccinated with a 7th dose of influenza virus vaccine (FLUZONE) IM in the left deltoid (lot U0881AA). On 10/23/2002, the pt developed a large reddened area at the injection site. The area was warm to the touch. The pt had a body temperature measurement of 98.2. Ice was applied and the pt was given acetaminophen (TYLENOL) as needed and methylprednisolone (MEDROL) as directed. On 10/25/2002, the pt was contacted and was improving. The pt was to continue methylprednisolone as directed. Subsequently, the pt recovered. The nurse also reported that a pt developed cellulitis, flushing, pyrexia, headache, injection site erythema, injection site inflammation, movement disorder and nausea (WAES #0210USA02344) and another pt developed injection site erythema, inflammation, swelling, pain in limb and drug hypersensitivity (WAES #0210USA02661) post vaccination with pneumococcal vaccine 23 polyvalent. No additional info is expected.
Pt had a very red, hot, and swollen arm after receiving the vaccination. Went to an urgent care MD. He told her to take Benadryl.
Mother states that she feels that the following is related to the vaccines. Child woke in the middle of the night unable to breathe. An ambulance was called & taken to ER. Diagnosis - Asthma. Mother states he had developed a rash on his back; front of trunk - 1-2 days before the asthma attack.
VOMITING; TIREDNESS; This spontaneous report received from a patient concerned a 72 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: high blood pressure, gi problems, hypothyroidism, anxiety, non smoker, and abstains from alcohol, and other pre-existing medical conditions included: The patient had no known drug allergy and no history of illicit drug use/abuse. The patient was previously treated with paracetamol for drug used for unknown indication. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 12-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included mirtazapine for anxiety, omeprazole for gi problems, enalapril maleate for high blood pressure, and levothyroxine sodium for hypothyroidism. On 12-MAR-2021, the patient experienced tiredness. On 16-MAR-2021, the patient experienced vomiting. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vomiting on 16-MAR-2021, and tiredness on 15-MAR-2021. This report was non-serious.
BP: 77/47  HR: 53 Pale Faintish  unconscious
A rash began on 8/17/01 around her mouth and the night of 8/20/01 was all over her body. She had a fever of 107F on 8/17/01 and 8/18/01 and baby didn't want to move her legs. She slept less, cried more than usual and fever only lasted 2 days. It was relieved with Motrin. The rash is ongoing. As of 8/21/01, the baby was acting normal.
Lightheadedness, diarrhea, racing heart.  Diarrhea only lasted a couple of hours - took Imodium.  Lightheadedness lasted off and on for 5 days.  Racing heart continues to happen off and on. Stopped drinking caffeinated coffee 4/2/21.   Went to physician on 4/5/21 and was noted to have elevated BP and some pre-ventricular contractions. Physician has me keeping a BP diary for 2 weeks and suggested I notify CDC of these symptoms. Still have days of elevated BP.
Patient started to exhibit swelling and extreme pain in his knees, fingers, ankles, and elbows.
Swelling, hot and very itchy at injection site along with pain in armpit, starting on 7th and 8th day after vaccination.
Mom reports lethargy & fever to 104 beginning 24 hrs p/vax; Persisted for 3 days saw MD; Next (4th) day developed "spots" - roseola - had been exposed w/o knowing it;
Received AVA #6 on 19Oct in left deltoid area. Pt noted that the vaccine site was red, swollen, pruritic and tender that evening and symptoms were worse upon awakening on 10/20/04. Increased tenderness with active ROM. Experienced difficulty sleeping last night due to pruritus and tenderness.
Older brother had shingle 3 ago. PT broke out with chickenpox on 2/13/03.
PATIENT RETURNED TO THE PHARMACY AND REPORTED THAT SHE FELT LIGHT-HEADED AND FLUSHED. I HAD THE PATIENT SIT ON THE BENCH AND I ASKED IF HER BREATHING WAS OK OR IF SHE COULD SWALLOW OK AND SHE SAID SHE COULD THAT SHE ONLY FELT LIGHT-HEADED. I HAD HER SIT FOR ABOUT 15 MINUTES WHILE I MONITORED HER CLOSELY. AFTER ABOUT 15 MINUTES SHE SAID SHE FELT WELL ENOUGH TO LEAVE AND HER AND HER HUSBAND EXITED THE STORE. I CALLED THE PATIENT AT HER HOME APPROXIMATELY 2 HOURS LATER AND CHECKED IN ON HER AND SHE SAID SHE WAS FEELING FINE.
ITP; platelet count has dropped 20 points every two days; tired; This is a spontaneous report from a contactable consumer reporting for spouse.  A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE),  dose 1 via an unspecified route of administration on an unspecified date in Jun2021 (Batch/Lot number was not reported) as a single dose for COVID-19 immunization.  The patient's medical history and concomitant medications were not reported.  The reporter states the patient has ITP. He received the first dose of the Pfizer BioNTech Covid-19 vaccine three weeks ago (as of report date 06Jul2021) and was scheduled to get his second dose at the pharmacy today or tomorrow. After the last dose, the pharmacy required him to wait for one hour after the dose was administered to monitor for adverse reactions. Since then, his platelet count has dropped 20 points every two days, and he got more and more tired. The outcome of the events was unknown. The reporter was asking where should her husband be for the second dose since his blood disorder puts him at risk for bleeding.   The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
Missed second dose date; 90 days since first dose; This spontaneous case was reported by a physician and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (90 days since first dose) and PRODUCT DOSE OMISSION ISSUE (Missed second dose date) in an 18-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0UU21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (90 days since first dose). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed second dose date). On 30-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (90 days since first dose) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (Missed second dose date) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were reported. No Treatment information was reported by the porter.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 18-Aug-2021: Follow up appended for document attachment contains no new information. On 18-Aug-2021: Follow up information contains event: Missed second dose date.
Within 10 minutes of receiving vaccines, developed rapid heart rate and chest pressure. Was seen at Urgent Care.
RIGHT ARM PAIN, FATIGUE, DIZZINESS, HEADACHES AND RIGHT ARM WEAKNESS SINCE 6/2021. SYMPTOMS ARE WORSENING AND BLOOD PRESSURE UNCONTROLLED WITH NEW MEDICATION.
pt recv vax 30JUN96 4AM & pt devel a large, red welt on forearm & inflammation, pain & swelling @ the inj site;
Case number PHEH2013US022709, is a combined initial and follow up spontaneous report from a pharmacist received on 29 Oct 2013 and on 05 Nov 2013 and a follow up report received from the nurse on 26 Nov 2013. This report refers to a 17-year-old female patient. Her medical history included amoxicillin allergy. No concomitant medication was reported. On 24 Oct 2013, she was accidentally vaccinated with 0.5 ml of Men A lyophilized conjugate of MENVEO, (batch number: X12098) which was reconstituted in a sterile water instead of MenCYW-135 liquid component. It was reported that she did not experienced any adverse event (no reaction) after the mal-administration. No other information was available. Follow-up report from the nurse received on 26 Nov 2013: Updated patient demographics and medical history.
double ear infection; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 52 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date Mar2021 (Lot number: EN6206) at the age of 52 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Known allergies: pcn" (unspecified if ongoing). There were no concomitant medications. The following information was reported: EAR INFECTION (non-serious) with onset 30Mar2021 05:30, outcome "not recovered", described as "double ear infection". The event "double ear infection" was evaluated at the physician office visit. Therapeutic measures were taken as a result of ear infection.  Additional information: Vaccine administration time=09:45 AM. Facility type vaccine other: No other vaccine in four weeks. No other medications in two weeks. No covid prior vaccination. Not covid tested post vaccination. Known allergies: pcn. Other medical history: none. Double ear infection after first dose. AE treatment: steroid started 5 days after 2nd dose of vaccine.  No follow-up attempts are possible. No further information is expected.
tested positive for COVID-19; very sick; This is a spontaneous report from a contactable consumer (patient). This 57-years-old male consumer received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot Number and expiry date was not reported), via an unspecified route of administration on 20Mar2021 (age at vaccination was 57-years-old male) as dose 1, single for COVID-19 immunization. Medical history was not reported. Concomitant medications were not reported. On an unspecified date following Tuesday after vaccination patient became sick and then he tested positive for COVID-19. Outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot been obtained.
Symptom onset of polyuria in Nov 2004; later developed polydipsia, decreased energy level, and blurred vision. Diagnosed with Type 1 Diabetes in Feb 2005. Information from follow up sent on 08/29/2005: See Enclosed medical records.